<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006143</url>
  </required_header>
  <id_info>
    <org_study_id>P1011</org_study_id>
    <secondary_id>11646</secondary_id>
    <secondary_id>ACTG P1011</secondary_id>
    <secondary_id>PACTG P1011</secondary_id>
    <nct_id>NCT00006143</nct_id>
  </id_info>
  <brief_title>Growth Hormone Treatment of Children With HIV-Associated Growth Failure</brief_title>
  <official_title>A Randomized, Open-Label Study of Recombinant Human Growth Hormone (r-hGH) in Children With HIV-Associated Growth Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of recombinant human growth&#xD;
      hormone (r-hGH) on growth in HIV-infected children.&#xD;
&#xD;
      Studies have shown that HIV-infected children do not grow at a normal rate and are shorter&#xD;
      than HIV-uninfected children who are the same age. Growth hormone has been used for many&#xD;
      years to treat children with growth hormone deficiency and has been safe and effective in&#xD;
      helping them to grow normally. The growth hormone to be used in this study, r-hGH, is an&#xD;
      investigational hormone (not yet approved by the Food and Drug Administration [FDA]) made in&#xD;
      the laboratory. It has helped HIV-positive adults gain weight and improve their physical&#xD;
      performance. This study has been changed to include a needle-free device for drug delivery&#xD;
      which will improve patient comfort and acceptability. Patients will no longer receive growth&#xD;
      hormone through traditional needles but through a needle-free device.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Wasting, or loss of lean tissue, is a serious consequence of AIDS. Body composition findings&#xD;
      in HIV-infected children are similar to those of HIV-uninfected children with classic growth&#xD;
      hormone deficiency. Evidence suggests that therapeutic administration of growth hormone (GH)&#xD;
      can induce anabolic effects, reverse pathologic catabolism, and perhaps even improve immune&#xD;
      function. As survival to adolescence and beyond improves with modern therapy in children with&#xD;
      HIV infection, it will become increasingly important to address the problems of stunting and&#xD;
      short stature in this population. [AS PER AMENDMENT 09/04/01: Recent evidence suggests that&#xD;
      needle-free delivery is preferred by young children below the age of ten years. Given the&#xD;
      advantages of a needle-free delivery system for the administration of growth hormone, most&#xD;
      significantly the reduction of risk for HIV contaminated needle-stick injuries to care&#xD;
      providers and other household members, it has been decided to use this method of study drug&#xD;
      delivery for all study participants.]&#xD;
&#xD;
      Children are assigned randomly to 1 of the following treatment groups:&#xD;
&#xD;
      Group 1: Children receive a single dose of r-hGH once a day. Group 2: Children receive half&#xD;
      the dose of r-hGH that Group 1 receives, once a day.&#xD;
&#xD;
      Group 3a: Children receive no r-hGH for the first 24 weeks [AS PER AMENDMENT 01/03/01: 48&#xD;
      weeks] of the study. After Week 24 [AS PER AMENDMENT 01/03/01: Week 48], they receive the&#xD;
      same dose as that of Group 1.&#xD;
&#xD;
      Group 3b: Children receive no r-hGH for the first 24 weeks [AS PER AMENDMENT 01/03/01: 48&#xD;
      weeks] of the study. After Week 24 [AS PER AMENDMENT 01/03/01: Week 48], they receive the&#xD;
      same dose as that of Group 2.&#xD;
&#xD;
      Subcutaneous injections are administered [AS PER AMENDMENT 09/04/01: using a needle-free&#xD;
      device], daily for 96 weeks in Groups 1 and 2; after 24 weeks [AS PER AMENDMENT 01/03/01: 48&#xD;
      weeks] on study, the treatment-delayed control group (Group 3) receives injections for 72&#xD;
      weeks [AS PER AMENDMENT 01/03/01: 48 weeks]. The first injection is at the clinic and&#xD;
      parents/guardians are trained how to prepare and administer the injections. Children are&#xD;
      closely monitored for toxicity, with dosing adjustments if needed. Evaluations and laboratory&#xD;
      tests are done at clinic visits every 4 weeks to determine growth indicators, body&#xD;
      chemistries, CD4 cell counts, HIV-1 RNA PCR, and anti-hGH antibodies and for routine&#xD;
      hematology testing, dietary intake assessment, and MRI scans. [AS PER AMENDMENT 01/03/01: MRI&#xD;
      scans are no longer performed.]&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">July 2002</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>102</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Children may be eligible for this study if they:&#xD;
&#xD;
          -  Are 4 to 12 years of age for girls, and 4 to 13 years of age for boys (consent of&#xD;
             parent/guardian is required).&#xD;
&#xD;
          -  Are HIV-positive.&#xD;
&#xD;
          -  Are not growing normally.&#xD;
&#xD;
          -  Have a normal intake of food each day.&#xD;
&#xD;
          -  Are able to walk.&#xD;
&#xD;
          -  Have been on stable anti-HIV therapy for at least 24 weeks before study entry and will&#xD;
             continue therapy for the entire duration of the study with no anticipated change in&#xD;
             therapy for the first 48 weeks of the study. (These therapy requirements reflect a&#xD;
             change.)&#xD;
&#xD;
          -  Are willing and able to follow study requirements.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Children may not be eligible for this study if they:&#xD;
&#xD;
          -  Had steady fever of 101 degrees F or higher during the 2 weeks before study entry.&#xD;
&#xD;
          -  Have a serious infection requiring medications within 30 days prior to study entry.&#xD;
&#xD;
          -  Are being fed through a vein.&#xD;
&#xD;
          -  Have severe diarrhea, intestinal bleeding or blockage, or are unable to absorb food.&#xD;
&#xD;
          -  Have cancer.&#xD;
&#xD;
          -  Have taken medications that may interfere with the study drug or have had radiation.&#xD;
&#xD;
          -  Have diabetes or a history of sugar intolerance.&#xD;
&#xD;
          -  Have carpal tunnel syndrome (unless it has been surgically repaired).&#xD;
&#xD;
          -  Have heart or kidney problems, or serious swelling of any kind.&#xD;
&#xD;
          -  Have any condition other than HIV infections that may have affected growth or that&#xD;
             makes it difficult to measure height.&#xD;
&#xD;
          -  Have any known allergies to the study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harland Winter</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Wayne Dankner</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Children's Hosp.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hosp. LA - Dept. of Ped., Div. of Clinical Immunology &amp; Allergy</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900276016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Maternal, Child, and Adolescent HIV CRS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida CDC Ft Lauderdale NICHD CRS</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Florida Jacksonville NICHD CRS</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Miami Ped. Perinatal HIV/AIDS CRS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Univ. School of Medicine, Dept. of Peds., Div. of Infectious Diseases</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Children's CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>606143394</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HMS - Children's Hosp. Boston, Div. of Infectious Diseases</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Health, Baystate Med. Ctr.</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobi Med. Ctr. Bronx NICHD CRS</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobi Med. Ctr.</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx-Lebanon Hosp. IMPAACT CRS</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem Hosp. Ctr. NY NICHD CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Med. Univ., Dept. of Peds.</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DUMC Ped. CRS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>277103499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hosp. CRS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VCU Health Systems, Dept. of Peds</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Hosp. Ram√≥n Ruiz Arnau, Dept. of Peds.</name>
      <address>
        <city>Bayamon</city>
        <zip>00956</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hosp. PR NICHD CRS</name>
      <address>
        <city>San Juan</city>
        <zip>009367344</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 7, 2000</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Outcome</keyword>
  <keyword>serostim</keyword>
  <keyword>Developmental Disabilities</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Failure to Thrive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

